Safety, cancer and Reproductive evidence

Assessment	Required evidence	Current implementation
Safety	Acceptable normal-tissue RNA / protein evidence across Vital, Protected and Manageable compartments.	Active. Only this assessment can supply Unsafe evidence. Manageable excess blocks CTA under the current rules.
Cancer expression	Expression in at least one measured cancer sample.	Active. One sample >0 native TPM/pTPM or reviewed reliable tumor protein. No normal-expression ratio.
Reproductive evidence	Affirmative expression in reproductive, placental, embryonic or fetal contexts.	Bulk RNA ≥5 nTPM, supported reproductive cell RNA ≥5 nTPM / ≥20 reads, reliable reproductive protein, or supported developmental RNA.

CTA: safety AND cancer expression AND Reproductive evidence, with complete required coverage, including the 52-context GTEx v11 core.
Reproductive includes reproductive organs, placenta, extraembryonic, embryonic and fetal contexts.
Diffuseness: HPA average N / (N + R) >10% blocks a complete adult/placental route. Disposable counts; Permissive thymus is excluded. Embryonic concentration is unassessed.
Only safety establishes Unsafe. Missing core data remain unassigned. **Other:** normal screen passes, CTA identity does not. Other records the unmet identity gate: reproductive evidence, cancer evidence or concentration. Abundance, support and adult Disposable expression are separate attributes.